Literature DB >> 20724167

Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.

Federico Filomia1, Francesca De Rienzo, M Cristina Menziani.   

Abstract

The DFG motif at the beginning of the activation loop of the MAPK p38alpha undergoes a local structural reorganization upon binding of allosteric type-II and type-III inhibitors, which causes the residue F169 to move from a buried conformation (defined as DFG-in) to a solvent exposed conformation (defined as DFG-out). Although both experimental and computer simulation studies had been performed with the aim of unveiling the details of the DFG-in to DFG-out transition, the molecular mechanism is still far from being unequivocally depicted. Here, the accelerated molecular dynamics (AMD) technique has been applied to model the active loop flexibility of p38alpha and sample special protein conformations which can be accessible only in some conditions or time periods. Starting from the assumption of an experimentally known initial and final state of the protein, the study allowed the description of the interaction network and the structural intermediates which lead the protein to change its loop conformation and active site accessibility. Besides a few important hydrogen bond interactions, a primary role seems to be played by cation-pi interactions, involving the DFG-loop residue F(169), which participate in the stabilization of an intermediate conformation and in its consequent transition to the DFG-out conformation. From this study, insights which may prove useful for inhibitor design and/or site directed mutagenesis studies are derived. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724167     DOI: 10.1016/j.bmc.2010.07.047

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  14 in total

1.  Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK.

Authors:  Natalie B Vinh; Jamie S Simpson; Peter J Scammells; David K Chalmers
Journal:  J Comput Aided Mol Des       Date:  2012-04-20       Impact factor: 3.686

2.  A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery.

Authors:  Timothy Cholko; Wei Chen; Zhiye Tang; Chia-En A Chang
Journal:  J Comput Aided Mol Des       Date:  2018-05-08       Impact factor: 3.686

3.  Insights from free-energy calculations: protein conformational equilibrium, driving forces, and ligand-binding modes.

Authors:  Yu-Ming M Huang; Wei Chen; Michael J Potter; Chia-En A Chang
Journal:  Biophys J       Date:  2012-07-17       Impact factor: 4.033

4.  A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.

Authors:  Mathew P Martin; Jin-Yi Zhu; Harshani R Lawrence; Roberta Pireddu; Yunting Luo; Riazul Alam; Sevil Ozcan; Said M Sebti; Nicholas J Lawrence; Ernst Schönbrunn
Journal:  ACS Chem Biol       Date:  2012-01-27       Impact factor: 5.100

Review 5.  p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.

Authors:  Valentina Grossi; Alessia Peserico; Tugsan Tezil; Cristiano Simone
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).

Authors:  Yan Li; Michel Delamar; Patricia Busca; Guillaume Prestat; Laurent Le Corre; Laurence Legeai-Mallet; RongJing Hu; Ruisheng Zhang; Florent Barbault
Journal:  J Comput Aided Mol Des       Date:  2015-03-26       Impact factor: 3.686

7.  Drugging MYCN through an allosteric transition in Aurora kinase A.

Authors:  William Clay Gustafson; Justin Gabriel Meyerowitz; Erin A Nekritz; Justin Chen; Cyril Benes; Elise Charron; Erin F Simonds; Robert Seeger; Katherine K Matthay; Nicholas T Hertz; Martin Eilers; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2014-08-28       Impact factor: 31.743

8.  Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response.

Authors:  Valentina Grossi; Micaela Liuzzi; Stefania Murzilli; Nicola Martelli; Anna Napoli; Giuseppe Ingravallo; Alberto Del Rio; Cristiano Simone
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

9.  Accurate calculation of mutational effects on the thermodynamics of inhibitor binding to p38α MAP kinase: a combined computational and experimental study.

Authors:  Shun Zhu; Sue M Travis; Adrian H Elcock
Journal:  J Chem Theory Comput       Date:  2013-07-09       Impact factor: 6.006

10.  Oroxylin A inhibits hemolysis via hindering the self-assembly of α-hemolysin heptameric transmembrane pore.

Authors:  Jing Dong; Jiazhang Qiu; Yu Zhang; Chongjian Lu; Xiaohan Dai; Jianfeng Wang; Hongen Li; Xin Wang; Wei Tan; Mingjing Luo; Xiaodi Niu; Xuming Deng
Journal:  PLoS Comput Biol       Date:  2013-01-17       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.